GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

Background: Given the broad age range across which the quadrivalent meningococcal ... vaccines did not reduce immune responses to diphtheria, tetanus, poliovirus, hepatitis B, Haemophilus ...

Hundreds have already taken advantage of the CLP’s free meningococcal B vaccination program, which provides protection for infants aged six weeks to two years, and teens aged 14 to 19 years.

The concomitant administration of multiple vaccines at a single ... post-vac Intergroup difference –5% Meningococcal hSBA titer ≥4 % of subjects with hSBA ≥1:8 or with seroresponse ...